Sida provides increased unrestricted funding of US$620,000 in 2018
IVI is pleased to announce that Sida**, the Swedish International Development Agency, is providing a further unrestricted contribution of SEK5 million (US$620,000) that the Institute will use to support three special high-priority projects in 2018.
These three new projects will include IVI laboratory assays to support a post-licensure study of the safety and effectiveness of Dengvaxia®* in dengue primed and non-primed children in Cebu, Philippines, ‘Modeling of the impact and cost-effectiveness of WHO’s “Ending Cholera - A Global Roadmap to 2030” strategy’ and ‘Conduct of a global economic burden assessment on antimicrobial resistance to typhoid fever treatments.’
*Dengvaxia®, manufactured by Sanofi Pasteur, is the only licensed dengue vaccine and to-date has been introduced in subnational public health programs in two countries; the Philippines and Brazil. Despite its overall positive public health impact in highly endemic settings, concerns have arisen about disease enhancement in dengue naïve vaccine recipients. The IVI project in Cebu will test blood samples collected prior to Dengvaxia® implementation to assess the effect of dengue primed status on vaccine safety. The results could make a significant contribution to our understanding of dengue, dengue hemorrhagic fever and potential interactions with dengue vaccines.
The second study on modeling and economic evaluation of cholera is expected to provide evidence on the value of investments and inform strategic decisions on cholera elimination and development of new vaccines. With antimicrobial resistance (AMR) being one of the biggest threats to global health, the third project will seek to estimate the economic implications of AMR on typhoid fever. These two projects will be led by IVI’s Policy and Economic Research (PER) Department.
**Sida is a long-term funder of IVI and is providing the Institute with support of SEK 35.5 million over the 5 years to 2019 in addition to this supplemental funding.